AI for Biology
Snapshot
What is this Market Category?
Why Now?
- Biological data and model scale have crossed a practical threshold. New companies are training foundation models on pathology images, protein sequences, molecular spectra, DNA, RNA, and other modalities; Bioptimus describes its objective as a universal biology model, while its H-optimus-0 model targets pathology. [2] [4]
- Protein and molecular design are becoming interactive software workflows. Latent Labs launched LatentX as a browser-based system for designing novel proteins, making model access available to academic institutions, biotech startups, and pharmaceutical companies rather than only specialized computational teams. [5]
- Capital formation has validated the category. Isomorphic Labs raised $600 million in its first external financing, led by Thrive Capital, demonstrating that investors are willing to fund AI-native drug-discovery platforms at a scale previously associated with major biotech companies. [6]
- Specialist foundation-model startups can now assemble differentiated biological data and talent. Latent Labs emerged from stealth with $50 million, including a $40 million Series A co-led by Radical Ventures and Sofinnova Partners. [7]
- AI is moving from prediction toward closed-loop experimentation. The investment thesis increasingly combines models, proprietary data, and laboratory execution; the resulting businesses aim not merely to annotate biology but to design experiments, generate candidates, and learn from experimental outcomes. This broader automation thesis is reflected in capital flowing to companies such as Lila Sciences and other AI–robotics platforms. [1]
What's Happening?
CAGR and TAM
- Publicly available search results do not provide a sufficiently reliable, directly accessible market-report source for a defensible standalone AI-for-Biology CAGR or TAM. The available evidence is stronger for the narrower AI-drug-discovery financing market than for the entire category.
- The most concrete current momentum figure is financing activity: AI-ML drug discovery and licensing reached $11 billion across 348 rounds in 2025, up from $8.9 billion across 264 rounds in 2024. [1]
- The $11 billion financing figure is not a market-revenue estimate; it is a deal-flow measure covering AI/ML drug discovery, licensing, venture funding, and related transactions. It should not be substituted for category TAM or software revenue. [1]
Category creation events
- Isomorphic Labs’ $600 million financing was a defining validation event: the Google DeepMind-linked company raised its first external round to build an AI-first drug-discovery platform. [6]
Capital concentration
- The funding pattern favors businesses that combine proprietary biological data, reusable models, and downstream therapeutic or laboratory applications. The market is therefore bifurcating between horizontal biology-model platforms and vertically integrated companies that use AI to advance their own drug pipelines. [2] [6] [1]
Market Incumbents
- Alphabet / Google DeepMind — supplies foundational AI research and has incubated Isomorphic Labs, an AI-first drug-discovery company. [6]
- NVIDIA — provides accelerated computing, scientific-AI infrastructure, and bioinformatics tooling used by life-science researchers and developers.
- Microsoft — offers cloud, AI, data, and genomics infrastructure to healthcare and life-science organizations.
- Amazon Web Services — provides cloud compute, machine learning, and data infrastructure for pharmaceutical and biotechnology workloads.
- IBM — participates in computational biology through enterprise AI, scientific computing, and quantum-computing research.
- Oracle — supplies enterprise data and cloud infrastructure to pharmaceutical, clinical, and healthcare organizations.
- Thermo Fisher Scientific — owns a major life-science tools and services footprint that can incorporate AI into instruments, analysis, and research workflows.
Alphabet / Google DeepMind
NVIDIA
Microsoft
Market Challengers
- Isomorphic Labs — Google DeepMind-linked drug-discovery company that raised $600 million in its first external financing. [6]
- Recursion — publicly traded, AI-native biotechnology company combining large-scale biological experiments with machine learning.
- Exscientia — AI-driven drug-design company that became a public-market reference point for computational therapeutics.
- Insilico Medicine — AI drug-discovery company combining target identification, molecular design, and an internal therapeutic pipeline; it reportedly raised a $110 million Series E. [3]
- Generate — generative-AI biotechnology company focused on designing therapeutic proteins.
- Terray Therapeutics — AI-enabled drug-discovery company using generative design and high-throughput experimentation; it closed a $120 million Series B. [3]
- Owkin — machine-learning company focused on biomedical data, precision medicine, and federated learning.
Isomorphic Labs
Insilico Medicine
Terray Therapeutics
Market Innovators
- Latent Labs — builds foundation models intended to make biology programmable; it emerged from stealth with $50 million. [7]
- Chai Discovery — develops AI models for molecular and protein-structure discovery; it initially raised nearly $30 million in seed funding. [3]
- EvolutionaryScale — develops large biological models for protein understanding and design.
- Zymergen — pioneered computationally guided biological engineering, although its later corporate trajectory makes its placement as an early-stage innovator historically rather than currently relevant.
- Profluent — applies generative models to protein and gene-editing design.
- Enveda Biosciences — uses AI and metabolomics to discover therapeutics from natural products; it unveiled the PRISM foundation model trained on 1.2 billion mass spectra. [3]
Latent Labs
Bioptimus
Chai Discovery
Industry Coverage and Market Data
Market Reports
- AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — sector transaction review covering venture rounds, licensing, M&A, and IPOs; it reports 348 financings and $11 billion in 2025 versus 264 rounds and $8.9 billion in 2024. [1]
- 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — company and financing survey focused on biology foundation models, protein design, RNA, mass spectrometry, and AI drug discovery. [3]
- BIO Financial Report 2025 — Illinois Biotechnology Innovation Organization — investor and company landscape highlighting companies using AI in drug discovery, diagnostics, and programmable biology. [9]
- AI for Drug Discovery Market — Grand View Research — relevant specialist market-report source, but the accessible search results did not expose enough report detail to responsibly quote its TAM, CAGR, geography, or forecast period.
- Artificial Intelligence in Healthcare Market — MarketsandMarkets — broader healthcare-AI framing that can provide an upper-bound context, though it includes many applications outside biology and drug discovery.
Industry Articles
- Latent Labs launches web-based AI model to democratize protein design — TechCrunch — reports LatentX’s browser-based protein-design workflow and the company’s backing. [5]
- 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — maps foundation-model companies across protein, RNA, pathology, mass spectrometry, and drug discovery. [3]
- Latent Labs emerges from stealth, raising $50M for programmable biology — Tech.eu — frames programmable biology as the company’s category thesis and reports its financing. [8]
- AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — provides a transaction-oriented view of the category’s maturation. [1]
Financial News Sources
- Google-backed AI drug discovery startup raises $600 million — Reuters — reports Isomorphic Labs’ first external financing and Thrive Capital’s lead role. [6]
- Latent Labs secures $50M in funding — Latent Labs — primary financing announcement detailing the $40 million Series A and syndicate. [7]
- Bioptimus Hits $76M Funding Milestone — Business Wire — reports the company’s $41 million round and $76 million cumulative funding. [2]
- Latent Labs emerges from stealth, raising $50M — Tech.eu — provides independent coverage of the financing and founding thesis. [8]
- AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs — 2025 Review — DealForma — reports financing concentration, IPO proceeds, M&A, and major rounds involving Isomorphic Labs, Pathos AI, and Lila Sciences. [1]
- 17 Companies Pioneering AI Foundation Models in Pharma and Biotech — BioPharmaTrend — consolidates financing signals for Bioptimus, Chai Discovery, Helical, Insilico, Terray, and Enveda. [3]
Frontier and Open Questions
- Can foundation models generate proprietary biological data, or will public pretraining remain sufficient? Terray’s model combines generative design with high-throughput experimentation, whereas model-first companies emphasize broad biological data and generalization. [3]
- Does automated experimentation belong inside AI for Biology or in a separate laboratory-robotics category? Lila Sciences and other AI–robotics companies push the boundary toward closed-loop discovery, while narrower definitions exclude physical laboratory infrastructure. [1]
- Can early AI-generated molecules outperform conventional discovery after clinical attrition is included? The category has attracted substantial financing, but financing volume is not equivalent to clinical validation; challengers with internal pipelines will determine whether the market becomes a durable therapeutic-development model. [6] [1]
Adjacent Concepts and Categories
- AI Drug Discovery — the narrower, therapeutics-focused subset of AI for Biology.
- Biological Foundation Models — reusable models trained on protein, DNA, RNA, pathology, molecular, or multimodal data.
- Generative Protein Design — computational creation and optimization of proteins, antibodies, enzymes, and other biologics.
- Self-Driving Laboratories — automated systems that select, execute, and learn from biological experiments.
- Scientific Data Infrastructure — data management, provenance, governance, and retrieval systems that make biological AI usable.
- Computational Biology — the established analytical discipline from which modern biology-AI applications emerged.
- Precision Medicine — patient-level diagnostics and treatment selection enabled by biological data and machine learning.
- Synthetic Biology — engineering biological systems, often using AI to design sequences, pathways, and experimental programs.
Sources
[1] 2026, Jan 13. dealforma.com . AI-ML Drug Discovery and Licensing R&D, M&A, Ventures and IPOs - 2025 ... . Updated: 2026, Nov 07. Generated: 2026, Nov 09. Perplexity API response.
[2] 2025, Jan 14. Business Wire . Bioptimus Hits $76M Funding Milestone and Prepares to ... . Updated: 2026, Oct 11. Generated: 2026, Nov 09. Perplexity API response.
[3] 2024, Jun 19. biopharmatrend.com . 17 Companies Pioneering AI Foundation Models in Pharma and ... . Updated: 2026, Oct 27. Generated: 2026, Nov 09. Perplexity API response.
[4] 2024, Feb 20. sofinnovapartners.com . Bioptimus . Updated: 2026, Nov 09. Generated: 2026, Nov 09. Perplexity API response.
[5] 2025, Jul 21. TechCrunch . Latent Labs launches web-based AI model to democratize protein design | TechCrunch . Updated: 2026, Nov 03. Generated: 2026, Nov 09. Perplexity API response.
[6] 2025, Mar 31. Reuters . Google-backed AI drug discovery startup raises $600 million . Updated: 2026, Oct 01. Generated: 2026, Nov 09. Perplexity API response.
[7] 2025, Feb 13. latentlabs.com . Latent Labs secures $50M in funding to realize the potential ... . Updated: 2026, Oct 02. Generated: 2026, Nov 09. Perplexity API response.
[8] 2025, Feb 13. tech.eu . AI pioneer Dr Simon Kohl's Latent Labs emerges from stealth, raising $50M for programmable biology . Updated: 2026, Nov 09. Generated: 2026, Nov 09. Perplexity API response.
[9] ibio.org . member investor portfolio report - 2025 . Updated: 2026, Nov 05. Generated: 2026, Nov 09. Perplexity API response.
[10] 2025, Nov 10. axios.com . Clio's $5b valuation, Klook's IPO, and Valar Atomics' giant A . Updated: 2026, Oct 26. Generated: 2026, Nov 09. Perplexity API response.